IDH2 and glioblastoma: Significantly, it should be brought to the forefront: although only accounted for a very small percentage, it really existed “IDH wild type and 1p/19q codeletion” oligodendroglioma and glioblastoma (GBM with oligodendrocyte components in the old version of WHO blue book) in practice.